FDA Drug Recalls
11,818 recalls · Class II, newest first
May 16, 2014
Class II · Moderate risk
Labeling: Label Error on Declared Strength; The outer light protective bags, where the ephedrine sulfate injection syringes are stored, were mislabeled with 25 mg/mL in big font and 5 mg/mL in small font, however, the actual syringes were correctly labeled as 25 mg/5 mL.
May 16, 2014
Class II · Moderate risk
Presence of Particulate Matter; metal embedded in the glass vial and visible particles floating in the solution
May 16, 2014
Class II · Moderate risk
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.
May 12, 2014
Class II · Moderate risk
Failed Dissolution Specifications: One lot of product is being voluntarily recalled because dissolution test results failed to meet specification throughout the product's shelf life.
May 8, 2014
Class II · Moderate risk
Presence of Foreign Tablets: Presence of atenolol 25 mg tablet mixed into promethazine 25 mg tablet bottles.
May 5, 2014
Class II · Moderate risk
Marketed without an Approved NDA/ANDA; product is being manufactured and distributed without a NDC number